RecruitingNot applicableNCT05925452

To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

Studying Juvenile idiopathic arthritis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Intervention: GenaKumab(drug)
Enrollment: 221 enrolled
Eligibility: 2-17 years · All sexes
Timeline: 2023 – 2028

Study locations (10)

Children's Hospital Affiliated to Capital Medical University, Beijing, Benjing, China
Children's Hospital Affiliated to Chongqing Medical University, Chongqing, Chongqing Municipality, China
Hunan Children's Hospital, Changsha, Hunan, China
Children's Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China
Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Affiliated Pediatric Hospital of Fudan University, Shanghai, Shanghai Municipality, China
Xi'an Children's Hospital, Xi’an, Shanxi, China
Chengdu Women and Children's Central Hospital, Chengdu, Sichuan, China
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05925452 on ClinicalTrials.gov

Other trials for Juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

See all trials for Juvenile idiopathic arthritis →

← Back to all trials